Abstract
In order to recover the costs of drug development, pharmaceutical companies must develop drugs for the global market. Problems doing so due to incompatible good clinical practice guidelines between Europe and the United States are discussed. Diyferences and similarities are identified and methods of facilitating compliance suggested.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
